Not Tagged
daiichi sankyo,astrazeneca
['$dsnky', '$azn']
#asco23 discussant dr kohei shitara suggests pantumour02 results needs to be considered in each tumour type, but points out orr competitive with other tumour agnostic approvals, and "should be discussed with regulators". (and doesn't seem convinced by her2 testing) $azn $dsnky 
Pharma and biotech reporter, found a home at Evaluate Vantage.